Grant: Project Grant - Priority Announcement: Infection and Immunity
University of Guelph
$100,000.00
AAV-vectored immunoprophylaxis for the prevention and treatment of infectious diseases
EF 2021-22
Résumé
Adeno-associated virus (AAV)-mediated expression of pathogen specific, broadly protective monoclonal antibodies (mAb) has been demonstrated to provide protection against a variety of infectious diseases in a range of animal models and is now being tested in two human clinical trials for human immunodeficiency virus (HIV) (NCT03374202 and NCT01937455). Our patented (U.S. patent US 10,806,802) AAV-mAb expression platform utilizes a novel, rationally engineered AAV6 mutant capsid, termed AAV6.2FF, which has been shown to be highly efficacious as a prophylactic against Ebola virus and C. Difficile toxin challenge, among other infectious diseases. In this proposal we aim to optimize and expand our vectored immunoprophylaxis (VIP) platform to aid in the clinical translation of this promising alternative vaccine and therapeutic strategy. Specifically, we will investigate AAV-vectored mAb expression kinetics, anti-drug antibody development, effect of pre-existing immunity, and ways to modulate gene expression and in a range of larger animal models including guinea pigs, ferrets, sheep, and non-human primates. Finally, we will implement novel vector design improvements and explore new applications for AAV-vectored mAb expression.
Programme
Project Grant - Priority Announcement: Infection and Immunity
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
456332
Name
Wootton Sarah
Region
Ontario; Alberta
Country
Canada; Canada
Orgtype
Research Institution; Institution Paid
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Virology & Viral Pathogenesis
Projecttitle
AAV-vectored immunoprophylaxis for the prevention and treatment of infectious diseases
Programtype2
Operating Grants
Orgnameinp2
University of Guelph
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Project Grant - Priority Announcement: Infection and Immunity
Keyworddelim
Adeno-Associated Virus (Aav); Alternative Vaccine Platform; Anti-Drug Antibodies; Emerging Infectious Diseases; Immunoprophylaxis; Large Animal Models; Marburg; Monoclonal Antibody; Respiratory Syncytial Virus; Sars-Cov-2
Abstract
Adeno-associated virus (AAV)-mediated expression of pathogen specific, broadly protective monoclonal antibodies (mAb) has been demonstrated to provide protection against a variety of infectious diseases in a range of animal models and is now being tested in two human clinical trials for human immunodeficiency virus (HIV) (NCT03374202 and NCT01937455). Our patented (U.S. patent US 10,806,802) AAV-mAb expression platform utilizes a novel, rationally engineered AAV6 mutant capsid, termed AAV6.2FF, which has been shown to be highly efficacious as a prophylactic against Ebola virus and C. Difficile toxin challenge, among other infectious diseases. In this proposal we aim to optimize and expand our vectored immunoprophylaxis (VIP) platform to aid in the clinical translation of this promising alternative vaccine and therapeutic strategy. Specifically, we will investigate AAV-vectored mAb expression kinetics, anti-drug antibody development, effect of pre-existing immunity, and ways to modulate gene expression and in a range of larger animal models including guinea pigs, ferrets, sheep, and non-human primates. Finally, we will implement novel vector design improvements and explore new applications for AAV-vectored mAb expression.
Competitiondate
202109
Approvedterm2
1 yr 0 mth
Pinamesdelim
Wootton, Sarah
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~